Spero Therapeutics, Inc. (SPRO) News
Filter SPRO News Items
SPRO News Results
|Loading, please wait...|
SPRO News Highlights
- SPRO's 30 day story count now stands at 9.
- Over the past 23 days, the trend for SPRO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DRUG, ACT and DE are the most mentioned tickers in articles about SPRO.
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
Spero Therapeutics (SPRO -2.2%) said the Biomedical Advanced Research and Development Authority (BARDA) awarded up to an additional $12.9M to the company to to develop tebipenem as a treatment for complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients. BARDA, a division under the U.S. Department of Health and Human Services,...
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 millionCAMBRIDGE, Mass., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, are expanding their existing partnership to de
The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed. The FDA's decision to lift the hold follows Spero's submission of a comprehensive study report with detailed analyses from the NHP toxic
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. “We are very pleased with the FDA’s decision and eager to bring SPR720 back into the clinic,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero. “Extensive ana
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections (c
Spero Therapeutics said the FDA will give priority review to its new-drug application for a drug that treats complicated urinary tract infections in adults.
Investment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Destra Investment Trust.
Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.95 and traded as low as $13.27. Spero Therapeutics shares last traded at $13.65, with a volume of 107,572 shares trading hands. Several brokerages have recently issued reports on SPRO. […]